RWM
NBIX icon

Ritholtz Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Ritholtz Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Buy
2,151
+454
+27% +$67.4K 0.01% 975
2026
Q1 		$224K Buy
1,697
+176
+12% +$23.4K ﹤0.01% 1093
2025
Q4 		$216K Buy
+1,521
New +$220K ﹤0.01% 1040

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ritholtz Wealth Management's NBIX Position: Q2 2026 in Review

Ritholtz Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 27% in Q2 2026, buying an estimated $67.4K and bringing the position to 2,151 shares worth $363K. The position accounts for 0.01% of the portfolio, ranked #975.

Ritholtz Wealth Management first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ritholtz Wealth Management held 2,151 shares of Neurocrine Biosciences worth $363K as of Q2 2026.
  • Ritholtz Wealth Management bought 454 Neurocrine Biosciences shares in Q2 2026, an estimated $67.4K.
  • Neurocrine Biosciences made up 0.01% of Ritholtz Wealth Management's portfolio in Q2 2026, its #975 holding.
  • Ritholtz Wealth Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.